CURGET: a combination of common-use polyphenols plus trimetazidine as metabolic therapy for Cancer: a theoretical proposal.

Authors

Pamela Pastrana-Peralta, Guadalupe Dominguez-Gomez, Adriana Romo-Pérez, Alma Chavez-Blanco, Aurora Gonzalez-Fierro, Alejandro García-Carrancá, Francisco Gutierrez-Delgado, Jose Correa-Basurto, Alfredo Cortes-Algara, Alfonso Duenas-Gonzalez

Published in

Expert opinion on pharmacotherapy. Oct 16, 2026. Epub Oct 16, 2026.

Abstract

Repurposing inexpensive oral compounds targeting metabolic reprogramming is a pragmatic strategy. CURGET is a five-node oral regimen designed to induce metabolic starvation in tumors.
Comprehensive literature search.The malignant phenotype features concurrent upregulation of glycolysis (HK2), glutaminolysis (GLS1), de novo lipogenesis (FASN), the mevalonate pathway (HMGR), and fatty-acid β-oxidation (FAO/3-KAT). CURGET combines four widely available polyphenols and a common cardiac drug: curcumin, urolithin A, resveratrol, EGCG, and trimetazidine to target these five enzymes. Additional mechanisms include context-dependent pro-oxidant activity and epigenetic modulation such as DNMT, HDAC, and HAT inhibition linked to cofactor depletion. This review synthesizes human safety and pharmacokinetic data, plasma AUC overlap with in vitro inhibitory concentrations, knockout evidence of metabolic plasticity, and clinical co-expression of HK2, GLS1, and FASN.
CURGET represents a coherent, low-cost oral strategy rather than a finalized protocol. Key priorities include developing bioavailable formulations, conducting preclinical studies with defined metabolic endpoints, and early-phase pharmacokinetic and safety assessments of the combination. If CURGET shows a favorable therapeutic index, it may be most applicable to metabolically characterized tumors, including gastric, pancreatic, and selected breast cancers. Successful development could improve access to affordable metabolic adjuncts and help reduce global disparities in cancer care.

PMID:
42885401
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.